Evidence map›Paper›PMID 41333445›Full record

ArticleResearch square2025

Single Cell and Spatial Transcriptomics Identify Novel Immune-Stromal Interactions in Cardiac Allograft Vasculopathy.

Macee C Owen, Daniel Yuhang Li, Haewon Shin, Wenduo Gu, Alekhya Parvathaneni, Farid F Kadyrov, Xiaoran Wang, Maura Sticco-Ivins, Gianni Bonnici, Samantha L Nelson and 12 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Macee C OwenDivision of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Daniel Yuhang LiDivision of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto CA.ORCID 0000-0003-1015-6298
Haewon ShinDivision of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Wenduo GuDivision of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto CA.ORCID 0000-0002-3859-3150
Alekhya ParvathaneniDivision of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Farid F KadyrovCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Xiaoran WangDivision of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO.
Maura Sticco-IvinsDepartment of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Gianni BonniciDepartment of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0009-0000-2739-8627
Samantha L NelsonDepartment of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Hao DunDepartment of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Sariah HyacinthDepartment of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Michael T CainDepartment of Surgery, Division of Cardiothoracic Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0003-4029-2557
Albert PedrozaDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA.ORCID 0000-0001-5291-5980
Alex DalalDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA.ORCID 0000-0002-9993-3817
Karim SallamDivision of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto CA.
Jack BoydDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA.
Joseph WooDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA.ORCID 0000-0002-2506-492X
Junedh M AmruteDivision of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-6851-0168
Paul ChengDivision of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto CA.ORCID 0000-0003-3429-2702
Kory J LavineDivision of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0003-1948-9945
Benjamin J KopeckyDepartment of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Washington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Christine T. Pham · 2018 to 2026
$7.6M
Specification and Function of Tissue Resident and Recruited Macrophages in Cardiac Remodeling and Heart FailureR35HL161185 · NHLBI · WASHINGTON UNIVERSITY · PI Kory J. Lavine · 2022 to 2026
$4.3M
Pediatric Cardiovascular and Pulmonary Research Training Program.T32HL125241 · NHLBI · WASHINGTON UNIVERSITY · PI Juliane Bubeck Wardenburg, Kory J. Lavine · 2015 to 2026
$4.1M
The Role of Donor Innate Immune Responses in Regulating Alloimmunity after Heart TransplantationR01HL151078 · NHLBI · WASHINGTON UNIVERSITY · PI KREISEL, DANIEL, LAVINE, KORY J. · 2020 to 2023
$2.6M
MACROPHAGE HETEROGENEITY IN HEART FAILURE PROGRESSION AND CARDIAC RECOVERYR01HL138466 · NHLBI · WASHINGTON UNIVERSITY · PI LAVINE, KORY J. · 2017 to 2021
$1.9M
MACROPHAGE ONTOGENY SHIFTS IN ISCHEMIC HEART DISEASER01HL139714 · NHLBI · WASHINGTON UNIVERSITY · PI LAVINE, KORY J. · 2018 to 2021
$1.5M
From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery DiseaseK08HL153798 · NHLBI · STANFORD UNIVERSITY · PI CHENG, PAUL PO SHENG · 2020 to 2024
$933k
Dissecting the Role of Donor CCR2- Macrophages During Acute Cellular Rejection After Heart TransplantationK08HL159359 · NHLBI · WASHINGTON UNIVERSITY · PI Benjamin J Kopecky · 2022 to 2026
$757k
Classical dendritic cells (cDC1) govern cardiac allograft toleranceF31AI194609 · NIAID · WASHINGTON UNIVERSITY · PI Macee Owen · 2025 to 2026
$77k
NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA091842NHLBI NIH HHS K08 HL153798NHLBI NIH HHS K08 HL159359NHLBI NIH HHS R01 HL138466NHLBI NIH HHS R01 HL139714NHLBI NIH HHS R01 HL151078NHLBI NIH HHS R35 HL161185NHLBI NIH HHS T32 HL125241NIAID NIH HHS F31 AI194609NIAMS NIH HHS P30 AR073752
6 · The paper itself

Abstract

Cardiac allograft vasculopathy (CAV) is the leading cause of mortality in heart transplant recipients. Despite the prevalence of CAV, there are no targeted therapeutic options to prevent or reverse disease progression, and patients ultimately require retransplant. CAV is defined by progressive neointimal hyperplasia in donor heart coronary arteries, leading to luminal obliteration and ultimately allograft failure or sudden cardiac death. Although immune and stromal cell interactions are believed to play a key role in CAV pathogenesis, the specific cellular players and molecular signals driving disease remain undefined. In this study, we leverage single-cell RNA sequencing and spatial transcriptomics of human coronary arteries to transcriptionally characterize CAV and define the neointimal microenvironment. We compare arteries with CAV to atherosclerotic coronary artery disease and non-disease controls to identify a unique CAV transcriptional signature. Integration of single-cell RNA sequencing and spatial transcriptomic datasets revealed that modulated vascular smooth muscle cells and macrophage subsets dominate the CAV neointima and suggest that these cells interact to propagate type 1 interferon (IFN)-mediated inflammation. In a mouse CAV model, we demonstrate that interferon blockade with Ruxolitinib significantly reduced the incidence of CAV and prolonged allograft survival. Collectively, this study offers a novel and detailed characterization of the unique cellular and transcriptional landscape of CAV and identify a candidate pathway that may underly CAV pathogenesis, which could serve as a new therapeutic target for this devastating disease.

Identifiers

PMID41333445
PMCPMC12668176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.